戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 k(cat)/K(m) against "poor" substrates (i.e., cefotaxime).
2 yzed by ESBLs in a manner similar to that of cefotaxime.
3  and the SHV-18-producing K. pneumoniae with cefotaxime.
4 rmediate and the transition to E' induced by cefotaxime.
5 ue ESBL, NC11, was not reduced with 4 mug/ml cefotaxime.
6 te a transition state analog for turnover of cefotaxime.
7 25-2 microg/mL and reduced susceptibility to cefotaxime.
8 s with improved resistance to the antibiotic cefotaxime.
9 tants with greatly improved activity against cefotaxime.
10 s prepared with 2 or 4 mug/ml ceftriaxone or cefotaxime.
11  Streptococcus pneumoniae to ceftriaxone and cefotaxime.
12  activity against the beta-lactam antibiotic cefotaxime.
13 e diarrhoea associated with increased use of cefotaxime.
14  and the majority of patients never received cefotaxime.
15 s, including oxyimino-cephalosporins such as cefotaxime.
16 llin, and the cephalosporins cephalothin and cefotaxime.
17 e when exposed to near-inhibitory amounts of cefotaxime.
18 eta-lactamase-carrying Escherichia coli with cefotaxime.
19 ling cephalosporins, such as Ceftriaxone and Cefotaxime.
20 6A Toho-1 beta-lactamase with the antibiotic cefotaxime.
21 ch residues for the cephalosporin antibiotic cefotaxime.
22  populations correlate with activity against cefotaxime.
23 y in addition to amoxicillin, ampicillin and cefotaxime.
24 aceae were also tested against ertapenem and cefotaxime.
25  confers resistance to ampicillin but not to cefotaxime.
26  in resistance to the beta-lactam antibiotic cefotaxime.
27 t to ampicillin (100%), tetracycline (100%), cefotaxime (100%), ceftazidime (100%), meropenem (100%),
28 loramphenicol (5.7%), meropenem (16.6%), and cefotaxime (11.8%).
29 f bacterial resistance to the combination of cefotaxime/13a.
30 bited a minimum inhibitory concentration for cefotaxime 20,000-fold higher than wild-type TEM-1 and a
31 r the first 4 days, a continuous infusion of cefotaxime (250 mg/kg/day) with simultaneous oral acetam
32 lin (72% of 13,531 isolates, 95% CI: 65-79), cefotaxime (27% of 6700 isolates, 95% CI: 12-44), chlora
33 onella, average across LMICs) and lowest for cefotaxime (33% and 19%).
34 ere cleared of infection when treated with a cefotaxime:5 combination.
35  10,777 nonmeningeal isolates tested against cefotaxime, 79.2% were susceptible, 14.3% were intermedi
36 icrodilution method with ceftazidime (86) or cefotaxime (91) alone or in combination with clavulanate
37 ssing wild-type HipA were highly tolerant to cefotaxime, a cell wall synthesis inhibitor, to ofloxaci
38 picillin and tobramycin (AT), ampicillin and cefotaxime (AC), or ampicillin, tobramycin and metronida
39 picillin and tobramycin (AT), ampicillin and cefotaxime (AC), or ampicillin, tobramycin, and metronid
40 onfirm our models' prediction that increased cefotaxime activity correlates with reduced Omega-loop f
41 cyl-enzyme and are not observed in the KPC-2:cefotaxime acyl-enzyme.
42                           Kinetic studies of cefotaxime acylation of the two PBP2x proteins confirmed
43 stitution causes a 1500-fold decrease in the cefotaxime acylation rate but a 5-fold increase in k (ca
44  Here, we assessed the impact of intravenous cefotaxime administration by analyzing longitudinal feca
45 ces the bactericidal activity of Ceftriaxone/Cefotaxime against highly pathogenic MRSA infection.
46                                      Whereas cefotaxime alone failed to cure mice infected with beta-
47 entration neither Inh2-B1 nor Ceftriaxone or Cefotaxime alone was able to inhibit the growth of bacte
48 nce genes that induce resistance patterns to cefotaxime, amoxicillin, and tetracycline, highlighting
49 orized 111 of 138 isolates as susceptible to cefotaxime and 114 of 138 as susceptible to ceftriaxone.
50 etive category errors ranged from 12.2% with cefotaxime and 9.8% with ceftriaxone (due mainly to clus
51 ction reliably detect these isolates if both cefotaxime and ceftazidime are tested, but only about ha
52 -encoded beta--lactamases were important for cefotaxime and ceftazidime resistance.
53 croScan Neg MIC panel type 32) that included cefotaxime and ceftazidime tested alone or with a fixed
54  to third-generation cephalosporins, such as cefotaxime and ceftazidime, increasing hospital mortalit
55 lyze third-generation cephalosporins such as cefotaxime and ceftazidime.
56 enzyme for the extended-spectrum antibiotics cefotaxime and ceftazidime.
57 xyimino-cephalosporins (ESOCs), for example, cefotaxime and ceftazidime.
58 xyimino-cephalosporins (ESOCs), for example, cefotaxime and ceftazidime.
59 inactivate, oxyimino-cephalosporins, such as cefotaxime and ceftazidime.
60                        Minor error rates for cefotaxime and ceftriaxone ranged from a low of 12.7% (E
61 m in diameter are predictably susceptible to cefotaxime and ceftriaxone, and those with smaller zones
62 orized 101 of 138 isolates as susceptible to cefotaxime and ceftriaxone.
63 eta-lactam antibiotics containing hydrolyzed cefotaxime and faropenem.
64 . marcescens isolates were resistant to both cefotaxime and gentamicin.
65 alosporin with the gram-positive activity of cefotaxime and the gram-negative spectrum of ceftazidime
66 preterm infants demonstrates that meropenem, cefotaxime and ticarcillin-clavulanate are associated wi
67 mpicillin, and cefotaxime, Escherichia coli, cefotaxime, and cefepime, Pseudomonas aeruginosa, pipera
68 isolates of K. oxytoca, MICs of ceftazidime, cefotaxime, and ceftizoxime were elevated for strains pr
69 parenteral cephalosporins, such as cefepime, cefotaxime, and ceftriaxone, by 9.1 to 13.0%, bringing t
70 ommended interpretive criteria, ceftriaxone, cefotaxime, and ciprofloxacin had 100% categorical agree
71 istance to penicillin (MIC, 1 microgram/ml), cefotaxime, and co-trimoxazole was common.
72 isolates was resistant to tetracycline, SXT, cefotaxime, and extremely high levels of penicillin and
73  amoxicillin-clavulanate, from 4% to 18% for cefotaxime, and from 5% to 27% for ciprofloxacin).
74 st-line antimicrobial treatment (ampicillin, cefotaxime, and gentamicin) based on the synopsis of int
75 All isolates were susceptible to penicillin, cefotaxime, and levofloxacin.
76 ntative classes of beta-lactams (ampicillin, cefotaxime, and meropenem) and at two different temperat
77 tive E. coli isolates that were resistant to cefotaxime, and sequence analysis confirmed that these p
78 early as high a risk of causing diarrhoea as cefotaxime, and the majority of patients never received
79 xacin and, to a lesser extent, azithromycin, cefotaxime, and trimethoprim all pose a significant risk
80                                              Cefotaxime- and ceftriaxone-resistant Streptococcus pneu
81 sceptibility to ampicillin, amoxicillin, and cefotaxime, antibiotics commonly used to treat S. pyogen
82 ts, while the requirements for hydrolysis of cefotaxime are more relaxed.
83 Conkey agar supplemented with ceftriaxone or cefotaxime as a screening method for accurately detectin
84  the other hand, however, the K(i) value for cefotaxime as an inhibitor of cephalothin hydrolysis is
85 with a general growth advantage, not only on cefotaxime but also on several other antibiotics that an
86  and provide resistance to the cephalosporin cefotaxime but not to the related antibiotic ceftazidime
87 a K(i) value of 89 nM and reduced the MIC of cefotaxime by 64-fold in CTX-M-9 expressing Escherichia
88 Of the 21 isolates, 3 showed a CA effect for cefotaxime by BMD but not by disk diffusion testing.
89  were intermediate, and 22 were resistant to cefotaxime by MIC testing; 138 isolates were susceptible
90 is suggested that the first few turnovers of cefotaxime by the P99 beta-lactamase may be different fr
91 e, steady state parameters for hydrolysis of cefotaxime by this enzyme are as follows: k(cat) = 0.41
92 results also demonstrate that azlocillin and cefotaxime can effectively kill in vitro doxycycline-tol
93 ting the active site is highly optimized for cefotaxime catalysis.
94 ses to 1 or more of ceftriaxone, cefuroxime, cefotaxime, cefepime, cefodizime, and ceftazidime; group
95  microdilution methodology with ceftazidime, cefotaxime, cefepime, cefpodoxime, and aztreonam.
96 picillin-sulbactam, ticarcillin-clavulanate, cefotaxime, cefotetan, ceftriaxone, cefoxitin, and imipe
97 methodology for susceptibility to aztreonam, cefotaxime, ceftazidime, and cefoxitin.
98 es were subjected to cefazolin, ceftriaxone, cefotaxime, ceftazidime, cefepime, and aztreonam agar di
99 cs containing an oxyimino group (cefuroxime, cefotaxime, ceftriaxone, ceftazidime, or aztreonam) was
100    The isolates had low MICs to amoxicillin, cefotaxime, ceftriaxone, doxycycline, linezolid, meropen
101 nly" interpretive criteria were proposed for cefotaxime, ceftriaxone, meropenem, azithromycin, and mi
102  isolates were susceptible to 6 antibiotics (cefotaxime, ceftriaxone, meropenem, rifampin, minocyclin
103 e isolates for which the MIC of ceftazidime, cefotaxime, ceftriaxone, or aztreonam was >or=2 microg/m
104 isolates (all E. coli) tested susceptible to cefotaxime, ceftriaxone, or ceftazidime.
105 isk breakpoints could not be established for cefotaxime, ceftriaxone, or meropenem using standard CLS
106 432) started WHO second-line cephalosporins (cefotaxime/ceftriaxone) (Group 2-"Low" Watch).
107  phenotypic AST for penicillin, amoxicillin, cefotaxime/ceftriaxone, erythromycin, trimethoprim-sulfa
108 ose generated by the inhibitory beta-lactams cefotaxime, cefuroxime, and cefoxitin.
109 and was selected for increased resistance to cefotaxime, cefuroxime, ceftazadime, and aztreonam, i.e.
110 were susceptible to penicillin, amoxicillin, cefotaxime, cefuroxime, erythromycin, chloramphenicol, v
111 he improved activity against ceftazidime and cefotaxime, consistent with observations first made for
112 portunistic pathogens capable of growth on a cefotaxime-containing medium (OPP-C), and carbapenem-res
113 e 30 mg/kg, then 20 mg/kg every 6 hours), or cefotaxime conventionally as boluses (62.5 mg/kg, 4 time
114 buted most to the loss rate of CFX, CFD, and cefotaxime (CTX) (t(1/2) = 4.5, 5.3, and 1.3 h, respecti
115 nhibitors able to potentiate the activity of cefotaxime (CTX) and ceftazidime (CAZ) against resistant
116 of key process parameters, on the removal of cefotaxime (CTX) from hospital wastewater using pistachi
117 lenge isolates were tested against cefepime, cefotaxime (CTX), ceftriaxone (CTR), clindamycin (CLI),
118 tential ESBL producers (ceftazidime [CAZ] or cefotaxime [CTX] MICs were > or =2 microg/ml for all iso
119 sitive; i.e., the BMD MICs of ceftazidime or cefotaxime decreased by >/=3 doubling dilutions in the p
120 s increased by >/=5 mm around ceftazidime or cefotaxime disks in the presence of CA.
121 g ESBL production, and both were superior to cefotaxime disks.
122 ory Standards criteria was lowest (24%) with cefotaxime disks.
123 combination drug treatment of azlocillin and cefotaxime effectively killed doxycycline-tolerant B. bu
124 red for hydrolysis of cephalosporins such as cefotaxime, either lysine or arginine is sufficient for
125 in mice that a combination of mecillinam and cefotaxime eliminates both wild-type and resistant CTX-M
126 e, Streptococcus agalactiae, ampicillin, and cefotaxime, Escherichia coli, cefotaxime, and cefepime,
127 ontrast, metagenomic analysis indicated that cefotaxime exposure did not significantly increase the o
128 niae isolates susceptible to ceftriaxone and cefotaxime from those that are not susceptible.
129  penicillin (from 21 percent to 25 percent), cefotaxime (from 10 percent to 15 percent), meropenem (f
130 shows that the most significant impact is on cefotaxime hydrolysis while ampicillin hydrolysis is lea
131 ning the acylation and deacylation rates for cefotaxime hydrolysis, we show that both rates are fast,
132 r221, thus explaining the increased level of cefotaxime hydrolysis.
133 mpicillin hydrolysis than one that catalyzes cefotaxime hydrolysis.
134 o Escherichia coli resistance to ampicillin, cefotaxime, imipenem or cephaloridine.
135 ed included cefoxitin-piperacillin, imipenem-cefotaxime, imipenem-ceftazidime, imipenem-piperacillin-
136 n TEM-1 towards resistance on the antibiotic cefotaxime in an Escherichia coli strain with a high mis
137     Our results indicate that mecillinam and cefotaxime in combination constrain resistance evolution
138 ld increased activity against the antibiotic cefotaxime in enzyme assays, and the mutant enzymes all
139 a micromolar concentration of Ceftriaxone or Cefotaxime in the presence of Inh2-B1.
140 d their populations predict activity against cefotaxime in vitro and in vivo.
141 ations of ten MBL variants in complex with a cefotaxime intermediate.
142    Overall, the new M100-S12 ceftriaxone and cefotaxime interpretative breakpoints for nonmeningeal i
143                 In the WT beta-lactamase the cefotaxime-like side chain is crowded against the Omega
144 , cefepime (VM error, 6.2%; m error, 13.0%), cefotaxime (m error, 21.2%), ceftriaxone (m error, 23.3%
145 mes, recovered from pig caeca on MacConkey + cefotaxime (McC + CTX) agar, as recommended by the Europ
146 t in January 2002 introduced ceftriaxone and cefotaxime MIC interpretative breakpoints of < or =1 mic
147           For a ceftazidime, ceftriaxone, or cefotaxime MIC of > or =2 microg/ml, a dichotomy existed
148 alothin analogue lowered the ceftazidime and cefotaxime minimum inhibitory concentrations (MICs) of E
149 had reduced susceptibilities to ceftriaxone, cefotaxime, minocycline, and ciprofloxacin.
150  Kinetic analyses show that KPC-2 hydrolyzes cefotaxime more efficiently than the bulkier ceftazidime
151 PenI demonstrates the highest kcat value for cefotaxime of 9.0 +/- 0.9 s(-1).
152  in vitro efficacy studies of azlocillin and cefotaxime on drug-tolerant persisters were done by semi
153 g in some medical centers, but 30-micrograms cefotaxime or 30-micrograms ceftriaxone disks are not re
154 en bonding to oximino cephalosporins such as cefotaxime or ceftazidime.
155 itidis, or H. influenzae in combination with cefotaxime or ceftriaxone.
156 e mutant proteins did not protect cells from cefotaxime or ofloxacin and had an impaired ability to p
157 occi (MICs >/=1 microgram/mL for penicillin, cefotaxime, or both).
158 = 3 x 10(-4) s(-1)) as compared with that of cefotaxime-PBP2x complex (3.5 x 10(-6) s(-1)).
159 cement of the deacylation rate was found for cefotaxime-PBP2x(R) complex (k(3) = 3 x 10(-4) s(-1)) as
160 rfold increase in resistance to methicillin, cefotaxime, penicillin G, and nafcillin.
161 d hydrolysis of nitrocefin, cephalothin, and cefotaxime relative to IMP-1.
162                               Interestingly, cefotaxime resistance emerges from mutations that are ne
163    Six of eight predicted mutations decrease cefotaxime resistance greater than 2-fold, while only on
164 her in cell culture, this inhibitor reversed cefotaxime resistance in CTX-M-producing bacteria.
165   As expected, one plasmid evolved increased cefotaxime resistance when appropriately strong cefotaxi
166  favor the divergence of one copy to improve cefotaxime resistance while maintaining the other copy t
167 picillin resistance) and for a new function (cefotaxime resistance).
168                       Point mutations confer cefotaxime resistance, but they compromise ampicillin re
169 stitute an adaptive path in the evolution of cefotaxime resistance.
170 hout cefotaxime supplementation to enumerate cefotaxime-resistant and generic E. coli.
171                      Hosts carrying both the cefotaxime-resistant and wild-type plasmids were then su
172         In multivariable models, generic and cefotaxime-resistant E. coli counts were 1.5-2 log highe
173 n 100% of soil vs 86% of concrete floors and cefotaxime-resistant E. coli on 89% of soil vs 43% of co
174                                              Cefotaxime-resistant E. coli prevalence on floors increa
175                  In total, 78 (13%, n = 590) cefotaxime-resistant isolates were obtained, of which 66
176                                 However, the cefotaxime-resistant plasmid maintained sufficient ampic
177 ngitis due to penicillin-, ceftriaxone-, and cefotaxime-resistant Streptococcus pneumoniae is describ
178 otaxime resistance when appropriately strong cefotaxime selection was applied.
179 tion model, and that taking antibiotics like cefotaxime should be thought of as a population rather t
180 oncentration (MIC) values to methicillin and cefotaxime showed increased rates of cell wall turnover
181                                Amoxicillin + cefotaxime shows the largest effects on both microbial c
182       During the binding and turnover of the cefotaxime substrate by this ES enzyme, it is proposed t
183  used IDEXX QuantiTray/2000 with and without cefotaxime supplementation to enumerate cefotaxime-resis
184  multi-drug resistance (MDR) to amoxicillin, cefotaxime, tetracycline, and gentamicin.
185  have tested two antibiotics, azlocillin and cefotaxime that were identified by us earlier.
186 ith resistance to ampicillin, gentamicin and cefotaxime, the current WHO recommended empiric regimens
187                     Steady state turnover of cefotaxime then largely involved E' as the free enzyme f
188 t of the initial enzyme form, E, which bound cefotaxime tightly, with a second more weakly binding fo
189    Analysis indicated that only two to three cefotaxime turnovers occurred during the K(i) determinat
190  well as the expanded-spectrum cephalosporin cefotaxime, using X-ray crystallography.
191 and chemotherapy with antineoplastic agents, cefotaxime, vancomycin, and ceftazidime.
192 xicillin were 8-fold higher, and the MIC for cefotaxime was 3-fold higher than for near-isogenic cont
193 xicillin were 8-fold higher, and the MIC for cefotaxime was 3-fold higher than for near-isogenic cont
194 e acyl enzyme adducts with cephaloridine and cefotaxime was confirmed by both electrospray and MALDI
195 overy was assessed, US-1 MacConkey agar with cefotaxime was used to further evaluate the reproducibil
196 ctams (including amoxicillin-clavulanate and cefotaxime) were isolated from scouring calves.
197 hin, cefaclor, cefuroxime, cefoperazone, and cefotaxime) were isolated, and the MBL variants were cha
198  confirmed from MacConkey agar with 4 mug/ml cefotaxime, where 45% and 16.6% of E. coli isolates phen
199 am antibiotics (ampicillin, amoxicillin, and cefotaxime), which reflects the usefulness of the sensor
200 lysis of the third generation cephalosporin, cefotaxime, which is hydrolyzed by the cp228 enzyme 10-f
201  tests (ceftazidime with clavulanic acid and cefotaxime with clavulanic acid) for ESBL confirmatory t
202 -lactam antibiotics such as penicillin-G and cefotaxime with normal, penicillin-susceptible PBP2x fro
203 , co-amoxiclav + gentamicin or amoxicillin + cefotaxime (ZEBRA study, Trial Register NL4882).

 
Page Top